<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312972</url>
  </required_header>
  <id_info>
    <org_study_id>209557</org_study_id>
    <nct_id>NCT03312972</nct_id>
  </id_info>
  <brief_title>Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy</brief_title>
  <acronym>F-Sharp</acronym>
  <official_title>F-SHARP: A Phase I/II Trial of Focal Salvage High-dose-rate BRachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to evaluate the safety and effectiveness of a technique called
      focal high-dose-rate (HDR) brachytherapy as treatment for prostate cancer that has come back
      in the prostate after prior radiotherapy. The study will examine the safety and efficacy of
      the treatment. The type of radiation that participants in this research will receive is
      targeted directly at the areas of the prostate where recurrent disease is evident, while
      avoiding treatment of the normal appearing prostate. This involves the placement of a
      radioactive material in the affected area of the prostate temporarily, where it remains for a
      short period of time, and then is subsequently removed using a minimally invasive technique
      called HDR Brachytherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of any radiation treatment plan is to achieve maximal disease response with minimal
      toxicity. HDR brachytherapy offers a promising definitive treatment option in the setting of
      Locally Recurrent Prostate Cancer after prior definitive radiation, based on the limited data
      described above, with achievement of biochemical disease control in a large percentage of
      patients with relatively low toxicity. With focal HDR brachytherapy, the investigators can
      treat the isolated areas of disease, while avoiding normal prostate tissue, with the goal of
      further improving toxicity rates. The investigators hypothesize that using single fraction,
      focal HDR brachytherapy performed with one single implant for the treatment of LRPC is
      feasible and without excess toxicity, and can be safely delivered. This should allow for
      better patient convenience and cost and improved treatment dosimetry and planning, as it will
      decrease the risk of catheter displacement between fractions, which will hopefully correlate
      to less GU and non-GU acute toxicity. The primary objective is to determine the acute and
      late GU and GI toxicity of single fraction focal HDR salvage brachytherapy (primary
      endpoint).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity rate</measure>
    <time_frame>24 months</time_frame>
    <description>The primary outcome in this study is the number of acute or chronic grade 3-5 toxicities as described by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Locally Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: HDR Brachytherapy implant, Up to 30 Gray (Gy) to target lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR Brachytherapy</intervention_name>
    <description>HDR Brachytherapy implant, deliver 1 fraction, Up to 30 Gray (Gy) to target lesion</description>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven locally recurrent adenocarcinoma of the prostate after the completion of
             definitive radiation therapy for initially diagnosed prostate cancer.

               -  Biopsy must be performed within 182 days of trial registration

               -  Biopsy should be a standard sextant biopsy AND either a targeted MR/ultrasound
                  guided biopsy or saturation biopsy or both.

          -  Initial cancer diagnosis that fits these specific criteria:

               -  Stages T1-T3a

               -  Nx or N0

               -  Mx or M0

          -  Eligible initial definitive radiotherapy modalities include:

          -  External beam radiotherapy, with photon or proton beam therapy

               -  Conventional or moderately hypofractionated radiotherapy

               -  Extremely hypofractionated external beam radiotherapy (Stereotactic body
                  radiation therapy)

          -  Definitive Brachytherapy:

               -  Low-dose rate

               -  High-dose rate

          -  Locally recurrent disease confined to the prostate +/- seminal vesicles and
             immediately adjacent tissue, as evaluated by the following:

               -  History/Physical examination

               -  Radiographically node negative disease (N0), as defined by CT or MR of pelvis +/-
                  abdomen within 6 months of registration.

               -  No evidence of bone metastases (M0) on bone scan within 6 months of registration.

               -  Fluciclovine-PET is encouraged, but not required

          -  Patients receiving ADT are eligible as long as they meet the other eligibility
             criteria. However, the duration of all ADT must be documented.

          -  Current ECOG Performance status Scale 0-2

          -  Current International Prostate Symptom Score (IPSS) &lt; 20

          -  The patient must be medically suitable to receive general anesthesia.

          -  The patient must be able and willing to sign a study-specific written informed consent
             form before study entry.

        Exclusion Criteria:

          -  Preregistration GI or GU toxicity (for any reason) grade ≥ 3 as defined in CTCAE
             version 4.03. That is, grade ≥ 3 GU or GI toxicity after first course of radiotherapy

          -  Patients receiving any other investigational agents.

          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection, severely symptomatic congestive heart failure, cardiac arrhythmia, recent
             myocardial infarction in last 6 months, or psychiatric illness/social situations that
             could limit compliance with study requirements.

          -  Patients who have received chemotherapy or immunotherapy within one month prior to
             study enrollment, other than ADT
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhishek Solanki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Chiappetta, BSN</last_name>
    <phone>708-216-2568</phone>
    <email>bchiappetta@lumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abhishek Solanki, MD</last_name>
    <phone>708-216-2556</phone>
    <email>Abhishek.Solanki@lumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Chiappetta, BSN</last_name>
      <phone>708-216-2568</phone>
      <email>bchiappetta@lumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Abhishek Solanki, MD</last_name>
      <phone>708-216-2556</phone>
      <email>abhishek.solanki@lumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Abhishek Solanki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matt Harkenrider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murat Surucu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Mysz, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyejoo Kang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahpa Plypoo, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gopal Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Flanigan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmer Farooq, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Baldea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Yacoub, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Shea, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Courtney Hentz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amishi Bajaj, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Korpics, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parekh A, Graham PL, Nguyen PL. Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review. Semin Radiat Oncol. 2013 Jul;23(3):222-34. doi: 10.1016/j.semradonc.2013.01.006. Review.</citation>
    <PMID>23763889</PMID>
  </reference>
  <reference>
    <citation>Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999 May 5;281(17):1598-604.</citation>
    <PMID>10235152</PMID>
  </reference>
  <reference>
    <citation>Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):327-33. Epub 2006 Nov 2.</citation>
    <PMID>17084558</PMID>
  </reference>
  <reference>
    <citation>Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, McBride S, Yamada Y, Zelefsky MJ. Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. J Urol. 2015 Dec;194(6):1624-30. doi: 10.1016/j.juro.2015.06.100. Epub 2015 Jul 10.</citation>
    <PMID>26165583</PMID>
  </reference>
  <reference>
    <citation>Ahmadi H, Daneshmand S. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Patient Relat Outcome Meas. 2014 Jul 5;5:63-70. doi: 10.2147/PROM.S52788. eCollection 2014. Review.</citation>
    <PMID>25045284</PMID>
  </reference>
  <reference>
    <citation>Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol. 2007 Feb;51(2):306-13; discussion 314. Epub 2006 Sep 11. Review.</citation>
    <PMID>17007995</PMID>
  </reference>
  <reference>
    <citation>Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, Larson TR, Wilkes MM, Navickis RJ. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology. 1999 Jan;53(1):2-10.</citation>
    <PMID>9886580</PMID>
  </reference>
  <reference>
    <citation>Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology. 1999 Nov;54(5):880-3.</citation>
    <PMID>10565751</PMID>
  </reference>
  <reference>
    <citation>Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J Contemp Brachytherapy. 2013 Mar;5(1):33-41. doi: 10.5114/jcb.2013.34342. Epub 2013 Mar 29.</citation>
    <PMID>23634153</PMID>
  </reference>
  <reference>
    <citation>Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004 Mar;171(3):1098-104.</citation>
    <PMID>14767279</PMID>
  </reference>
  <reference>
    <citation>Yamada Y, Kollmeier MA, Pei X, Kan CC, Cohen GN, Donat SM, Cox BW, Zelefsky MJ. A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy. 2014 Mar-Apr;13(2):111-6. doi: 10.1016/j.brachy.2013.11.005. Epub 2013 Dec 25.</citation>
    <PMID>24373762</PMID>
  </reference>
  <reference>
    <citation>Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):324-9. doi: 10.1016/j.ijrobp.2013.01.027. Epub 2013 Mar 6.</citation>
    <PMID>23474112</PMID>
  </reference>
  <reference>
    <citation>Peters M, Maenhout M, van der Voort van Zyp JR, Moerland MA, Moman MR, Steuten LM, van Deursen MJ, van Vulpen M. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol. 2014 Jul;112(1):77-82. doi: 10.1016/j.radonc.2014.06.013. Epub 2014 Jul 3.</citation>
    <PMID>24998704</PMID>
  </reference>
  <reference>
    <citation>Sasaki H, Kido M, Miki K, Kuruma H, Takahashi H, Aoki M, Egawa S. Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy. Int J Urol. 2014 Jun;21(6):572-7. doi: 10.1111/iju.12373. Epub 2013 Dec 23.</citation>
    <PMID>24372730</PMID>
  </reference>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <reference>
    <citation>Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996 Dec;49(12):1373-9.</citation>
    <PMID>8970487</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Abhishek Solanki</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>HDR Brachytherapy</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data (IPD) available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

